Maze Therapeutics, Inc.
MAZE
$25.56
-$0.87-3.29%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 20.00M | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 20.00M | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 20.00M | -- | -- | -- | -- |
| SG&A Expenses | 12.41M | 10.49M | 7.78M | 8.37M | 7.82M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 46.55M | 38.06M | 32.97M | 36.47M | 35.40M |
| Operating Income | -26.55M | -38.06M | -32.97M | -36.47M | -35.40M |
| Income Before Tax | -24.21M | -34.57M | -30.09M | -33.68M | -32.79M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -24.21M | -34.57M | -30.09M | -33.68M | -32.79M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -24.21M | -34.57M | -30.09M | -33.68M | -32.79M |
| EBIT | -26.55M | -38.06M | -32.97M | -36.47M | -35.40M |
| EBITDA | -26.11M | -37.56M | -32.39M | -35.83M | -34.72M |
| EPS Basic | -0.45 | -0.65 | -0.66 | -0.77 | -1.15 |
| Normalized Basic EPS | -0.28 | -0.40 | -0.41 | -0.48 | -0.72 |
| EPS Diluted | -0.45 | -0.65 | -0.66 | -0.77 | -1.15 |
| Normalized Diluted EPS | -0.28 | -0.40 | -0.41 | -0.48 | -0.72 |
| Average Basic Shares Outstanding | 53.90M | 53.40M | 45.78M | 43.80M | 28.63M |
| Average Diluted Shares Outstanding | 53.90M | 53.40M | 45.78M | 43.80M | 28.63M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |